Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progress
31 août 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
14 juin 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Announces Key Appointments to Strengthen Research and Development Team
23 mai 2017 07h00 HE
|
Summit Therapeutics PLC
Dr David Roblin to combine Chief Operating Officer and Chief Medical Officer roles Dr Anne Heatherington appointed Head of Clinical Development and Quantitative SciencesDr Dave Powell appointed Head...
Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
28 avr. 2017 18h30 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
29 mars 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, March 29, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings
01 févr. 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
15 déc. 2016 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress
08 sept. 2016 07h00 HE
|
Summit Therapeutics PLC
Conference call to be held 1:00pm BST / 8:00am EDT OXFORD, United Kingdom, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development...
Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection
20 juin 2016 12h30 HE
|
Summit Therapeutics PLC
Microbiome-Sparing Action of Ridinilazole associated with Superiority over Vancomycin in Sustained Clinical Response Rate OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Summit...
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
02 juin 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...